Battle to get fiercer over local anti-ulcer market

Published: 2009-12-08 06:57:00

Updated: 2009-12-08 06:57:00

Korean drug makers are expected to wage fiercer campaigns to raise domestic anti-ulcer market share amid forecasts that Ilyang Pharm will emerge as a strong competitor with its Noltec (ilaprazole) new proton pump inhibitor.

Ilyang is accelerating its aggressive marketing activities, publicizin...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK